Intravitreal MPTP drives retinal ganglion cell loss with oral nicotinamide treatment providing robust neuroprotection

• Published in: Acta neuropathologica communications Vol. 12; no. 1; pp. 79 - 16
• Main Authors: Rombaut, Anne, Jovancevic, Danica, Wong, Raymond Ching-Bong, Nicol, Alan, Brautaset, Rune, Finkelstein, David I, Nguyen, Christine T O, Tribble, James R, Williams, Pete A
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 21.05.2024; BioMed Central; BMC
• Subjects: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine - pharmacology; Administration, Oral; Animals; Astrocyte; Disease Models, Animal; Ganglion; Intravitreal Injections; Male; Medical research; Medicin och hälsovetenskap; Medicine, Experimental; Mice; Mice, Inbred C57BL; Microglia; MPTP; MPTP Poisoning - drug therapy; MPTP Poisoning - metabolism; MPTP Poisoning - pathology; Müller glia; Nervous system diseases; Neurons; Neuroprotective Agents - administration & dosage; Neuroprotective Agents - pharmacology; Niacinamide; Niacinamide - administration & dosage; Niacinamide - pharmacology; Parkinsonian Disorders - drug therapy; Parkinsonian Disorders - metabolism; Parkinsonian Disorders - pathology; Retina; Retinal ganglion cell; Retinal Ganglion Cells - drug effects; Retinal Ganglion Cells - metabolism; Retinal Ganglion Cells - pathology; Müller glia; Retina; Astrocyte; MPTP; MPP; Parkinson’s disease; Microglia; Retinal ganglion cell

Neurodegenerative diseases have common underlying pathological mechanisms including progressive neuronal dysfunction, axonal and dendritic retraction, and mitochondrial dysfunction resulting in neuronal death. The retina is often affected in common neurodegenerative diseases such as Parkinson's...